MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0000000000004153

Медицинская библиотека · AIDS (London, England) · 2025

'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV.

Baldin Gianmaria, Salvo Pierluigi Francesco, Passerotto Rosa Anna, Iannone Valentina, Lamanna Francesco, Carbone Andrea, Farinacci Damiano, Lombardi Francesca, Borghetti Alberto, Di Giambenedetto Simona, Torti Carlo, Ciccullo Arturo

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine is a well tolerated option for simplification in people with HIV (PWH). We aimed to assess long-time effectiveness and safety in our cohort.

METHODS

We performed an observational study enrolling HIV-1-infected, virologically suppressed PWH, switching to dolutegravir plus lamivudine. Exclusion criteria were HBV-coinfection and the presence of the M184V mutation before the simplification. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥200 copies/ml or by two consecutive HIV-RNA ≥ 50 copies/ml) and treatment discontinuation (TD, defined as the interruption of either 3TC or DTG).

RESULTS

Six hundred thirty-one PWH were considered for the analysis: 446 were males (70.7%), with a median age of 51.1 years [interquartile range (IQR) 42.6-57.6]. Estimated probabilities of maintaining virological suppression at 192 and 384 weeks were 95.1% [95% confidence interval (CI) 92.0-96.2] and 91.5% (95% CI 87.1-94.4), respectively. At multivariable analysis, including zenith HIV-RNA, time of virological suppression before switch, risk factors for HIV infection and age, only intravenous drug users (IDU) [versus other risk factors, adjusted hazard ratio (aHR) 3.58, 95% CI 1.38-9.28, P  = 0.009] independently predicted VF. A border-line significant association with VF emerged for age (per 10-years more, aHR 0.72, 95% CI 0.51-1.01, P  = 0.058) and zenith HIV-RNA >500 000 cps/ml (versus. <500 000 cps/ml, aHR 2.31, 95% CI 0.98-5.46, P  = 0.056).As to treatment tolerability, estimated probabilities of remaining on study regimen at 192 and 384 weeks were 87.8% (95% CI 84.5-90.5) and 85.1% (95% CI 81.0-88.5), respectively.

CONCLUSIONS

Our findings confirm the long-term effectiveness and tolerability of dolutegravir plus lamivudine in virologically suppressed PWH.

Для цитирования: Baldin Gianmaria, Salvo Pierluigi Francesco, Passerotto Rosa Anna, Iannone Valentina, Lamanna Francesco, Carbone Andrea, Farinacci Damiano, Lombardi Francesca, Borghetti Alberto, Di Giambenedetto Simona, Torti Carlo, Ciccullo Arturo. 'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV.. AIDS (London, England). 2025. DOI: 10.1097/qad.0000000000004153.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.